Directorate Change

Oxford Pharmascience Group Plc

("Oxford Pharmascience" or the "Company")

Appointment of Non-Executive Board Director

Oxford Pharmascience (AIM: OXP), the specialty pharmaceutical company that redevelops medicines to make them better, safer and easier to take, today announces the appointment of John Goddard, aged 62,  to its Board of Directors. Mr. Goddard has an impressive track record in the global pharmaceutical industry with significant experience in business development.

John Goddard has had a distinguished career in the global pharmaceutical industry, the majority of which was with AstraZeneca, where he was ultimately Head of Group Strategic Planning and Business Development. Prior to his retirement from AstraZeneca in 2010, he was responsible for a 100 strong global team focused on M&A and licensing, which completed around 75 transactions in four years including several acquisitions, in-licensing and out-licensing of compounds and disposals. Latterly, Mr. Goddard became Chairman of two AstraZeneca subsidiaries, Aptium Oncology in the US and Astratech in Sweden. He is currently a member of the Board of Directors of Optos PLC and IntasPharmaceuticals Limited. Mr Goddard is a Fellow of the Institute of Chartered Accountants and a Member of the Association of Corporate Treasurers.

Commenting on the appointment Dave Norwood, Non-Executive Chairman of Oxford Pharmascience said, "We welcome John Goddard to the Oxford Pharmascience Board as an independent non -executive director. His experience in the industry brings a valuable skill to the Board as it initiates the commercialisation of the lead products in its pipeline."

Commenting on his appointment, John Goddard said, "I am pleased to be invited to join the Board of Oxford Pharmascience and I look forward to applying my experience to assisting the future development of the company."

John Goddard is currently a director of Optos PLC and Medical Devices Intas Pharmaceutical Limited (India). John Goddard served as a Director of Renovo Group PLC from 1 February 2008 to 30 June 2011. There are no other matters which are required to be announced with regard to this appointment under paragraph (g) of Schedule 2 of the AIM Rules or the AIM Rules.

Contacts:

Contacts:

Oxford Pharmascience +44 20 7554 5875

Marcelo Bravo, Chief Executive

N+1 Singer +44 20 7496 3000

Aubrey Powell / Jen Boorer

About Oxford Pharmascience Group Plc

Oxford Pharmascience Group Plc uses a range of proprietary technology platforms to re-develop existing medicines to make them better, safer or easier to take. The Company does not manufacture or sell its own pharmaceutical products direct to consumers but instead seeks to license its technologies and dossiers to a network of partners, mainly leading pharmaceutical companies with Rx (prescription) and OTC (Over the Counter) branded portfolios.

Oxford Pharmascience Group Plc focuses on existing medicines that are proven to be safe and effective but nevertheless still have associated issues and side effects often affecting compliance. By working with such medicines the Company is able to develop new innovative products for a fraction of the cost, in much quicker timescales and without the high risk of failure associated with developing new drugs.